|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
Schizoaffective disorder |
|
Schizophrenia |
| |
|
|
SIDE EFFECTS:
|
|
Cardiovascular effects, specifically tachycardia |
|
hypotension |
|
orthostatic hypotension |
|
fever |
|
Agitation |
|
akathisia |
|
confusion |
|
difficulty in accommodation |
|
electrocardiogram (ECG) changes |
|
hypertension |
|
syncope |
|
Blood dyscrasias, specifically agranulocytosis |
|
eosinophilia |
|
granulocytopenia |
|
leukopenia |
|
thrombocytopenia |
|
deep-vein thrombosis |
|
pulmonary embolism |
|
extrapyramidal effects, specifically akinesia or hypokinesia |
|
rigidity |
|
tremor |
|
hepatitis |
|
hyperglycemia |
|
impotence |
|
insomnia or disturbed sleep |
|
mental depression |
|
neuroleptic malignant syndrome (NMS) |
|
seizures |
|
tardive dyskinesia |
|
trouble in urinating |
|
Constipation |
|
dizziness or lightheadedness |
|
drowsiness |
|
headache |
|
hypersalivation |
|
nausea or vomiting |
|
unusual weight gain |
|
Abdominal discomfort or heartburn |
|
dryness of mouth |
|
hyperhidrosis |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Cardiovascular disorders |
|
>> Glaucoma, narrow-angle, predisposition to |
|
>> Intestinal motility impairment |
|
>> Prostatic hypertrophy |
|
Hepatic function impairment |
|
Renal function impairment |
|
>> Seizure disorders |
|
|
ADULT DOSE:
|
|
Antipsychotic-Oral, initially 12.5 mg (one half of a 25-mg tablet) one or two times a day, the dosage being increased in increments of 25 to 50 mg a day, if tolerated, to achieve a dose of 300 to 450 mg a day by the end of two weeks. Subsequent dosage increments should not exceed 100 mg one or two times a week .
If reinitiating clozapine treatment two or more days since the last dose was taken, an initial dosage of 12.5 mg (one half of a 25-mg tablet) one or two times a day is recommended. However, titration to an effective dosage may proceed more rapidly than initial titration if the medication is well-tolerated. In any patient who experienced respiratory or cardiac arrest during initial dosing but who was then successfully titrated to a therapeutic dosage, titration of clozapine following reinitiation should proceed with great caution after an interruption in therapy of ³ 24 hours duration.
Note: For malnourished patients, or those with hepatic, renal, or cardiovascular disease, dosage should be titrated more slowly than for other patients . |
|
MAXIMUM ADULT DOSE:
|
|
900 mg per day .
|
|
PEDIATRIC DOSE:
|
|
Children younger than 16 years of age-Safety and efficacy have not been established . |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|